The University Diabetes Centre at King Saud University Medial CIty
Riyadh, Saudi Arabia
Location status: Recruiting
NCT Number: NCT06513247
Type 1 diabetes mellitus (T1D) is a growing public health concern in Saudi Arabia, ranking ninth globally in T1D incidence and tenth in T1D prevalence in children, and the rates are expected to rise and incur greater healthcare costs. Genetic and immunological factors are believed to play a significant role in disease development, and recent clinical trials have shown promise in delaying or preventing T1D onset in high-risk individuals. Early screening for immunological or genetic markers in children is crucial to identify high-risk individuals and provide early intervention. Last year, the American diabetes association's recommended clinicians to screen first degree relatives of individual with T1D. Unfortunately, Saudi Arabia and other Arab countries lack established T1D screening programs, making early identification and intervention challenging. The benefits of screening include education for symptom awareness, monitoring to track progression to clinical T1D, a five-fold reduction in diabetic ketoacidosis (DKA) at onset, and improved glucose control for the first years following diagnosis. To address this issue, exploring effective and efficient screening methods in identifying high-risk children and the cultural acceptability, feasibility, and barriers to a broader implementation of such screening programs among Saudi families is crucial. Therefore, the investigators aim to conduct a prospective cohort study among young children and adolescents with a family history of T1D (i.e., T1D first-degree relatives). Children 2-18 years old will be screened using a 5 spots filter-dried blood sample for the following:
1. Islet autoantibodies: IAA, GADA, IA-2A, Zn-transporter autoantibodies using the antibody detection by agglutination PCR (ADAP) assay. 2. HLA phenotyping 3. Genetic risk score after the cross-sectional assessment those who are determined to be in stage I, or II of T1D will be offered prospective follow-up for 5 years.
Interested in participating?
Request Info2 year–18 year
All sexes
Observational
Riyadh, Saudi Arabia
Location status: Recruiting
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Diabetes is defined based on the American diabetes association (ADA) definition: Classic symptoms of diabetes or hyperglycemic crisis, with plasma glucose concentration ≥11.1 mmol/L (200 mg/dL), or Fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dL). Fasting is defined as no caloric intake for at least 8 h, or Two-hour post load glucose ≥11.1 mmol/L (≥200 mg/dL) during an OGTT, or HbA1c >6.5%.
Exclusion criteria
IAA, GADA, IA-2A, Zn-transporter 8 autoantibodies
using DBS filter paper
Time frame: 6 months
Time frame: 6 months
measured as number of participants that they refused to be screened.
Time frame: 12 months
measured as number of participants who complete the screening.
Time frame: 6 months
Time frame: 5 years
Time frame: 5 years
Time frame: 1 year
measured by the generalized anxiety disorder -7 scale (GAD-7)
Time frame: 5 years
measured by oral glucose tolerance test
Interested in participating?
Request InfoKing Saud University
Other
Feasibility of a Pilot Screening Program for Type 1 Diabetes in a High-Risk Population
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05463289
Autoimmune Diseases, Cardiovascular Diseases
Baltimore, Maryland, United States
View Trial DetailsNCT06783309
Autoimmune Diseases, Diabetes Mellitus
Tucson, Arizona, United States
View Trial DetailsNCT07593625
Autoimmune Diseases, Diabetes (DM)
Christchurch, New Zealand
View Trial DetailsNCT06273631
Autoimmune Diseases, Diabetes Mellitus
Nanjing, Jiangsu, China
View Trial Details